Literature DB >> 9102227

Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.

J C Reubi1, J C Schaer, B Waser.   

Abstract

Cholecystokinin (CCK)-A and CCK-B/gastrin receptors were evaluated with in vitro receptor autoradiography in 406 human tumors of various origins using a sulfated 125I-labeled CCK decapeptide analogue 125I-(D-Tyr-Gly, Nle28,3l)-CCK 26-33 and 125I-labeled Leu15-gastrin as radioligands. CCK-B/gastrin receptors were found frequently in medullary thyroid carcinomas (92%), in small cell lung cancers (57%), in astrocytomas (65%), and in stromal ovarian cancers (100%). They were found occasionally in gastroenteropancreatic tumors, breast, endometrial, and ovarian adenocarcinomas. They were either not expressed or rarely expressed in colorectal cancers, differentiated thyroid cancers, non-small cell lung cancers, meningiomas, neuroblastomas, schwannomas, glioblastomas, lymphomas, renal cell cancers, prostate carcinomas, and the remaining neuroendocrine tumors (i.e., pituitary adenomas, pheochromocytomas, paragangliomas, and parathyroid adenomas). CCK-A receptors were expressed rarely in tumors except in gastroenteropancreatic tumors (38%), meningiomas (30%), and some neuroblastomas (19%). The identified CCK-A and CCK-B receptors were specific and of high affinity in the subnanomolar range. The rank order of potency of various CCK analogues was: sulfated CCK-8 = L-364,718 >> nonsulfated CCK-8 = L-365,260 > or = gastrin for CCK-A receptors and sulfated CCK-8 > gastrin = nonsulfated CCK-8 > L-365,260 > L-364,718 for CCK-B receptors. CCK-B receptors could also be selectively and specifically labeled with a newly designed nonsulfated 125I-(D-Tyr-Gly, Nle28,31)-CCK 26-33. Gastrin mRNA measured by in situ hybridization was present in most CCK-B receptor-positive small cell lung cancers, breast tumors, and ovarian tumors, representing the molecular basis of a possible autocrine growth regulation of these tumors. Gastrin and CCK mRNAs were lacking in medullary thyroid cancers. Thus, these results may have pathogenic, diagnostic, differential diagnostic, and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9102227

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  92 in total

1.  Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast.

Authors:  M Gugger; J C Reubi
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Peptides and Gd complexes containing colloidal assemblies as tumor-specific contrast agents in MRI: physicochemical characterization.

Authors:  Mauro Vaccaro; Antonella Accardo; Gerardino D'Errico; Karin Schillén; Aurel Radulescu; Diego Tesauro; Giancarlo Morelli; Luigi Paduano
Journal:  Biophys J       Date:  2007-05-04       Impact factor: 4.033

3.  Are there tumor suppressor genes on chromosome 4p in sporadic colorectal carcinoma?

Authors:  Hai-Tao Zheng; Li-Xin Jiang; Zhong-Chuan Lv; Da-Peng Li; Chong-Zhi Zhou; Jian-Jun Gao; Lin He; Zhi-Hai Peng
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

4.  Micelles obtained by aggregation of gemini surfactants containing the CCK8 peptide and a gadolinium complex.

Authors:  Antonella Accardo; Diego Tesauro; Anna Morisco; Gaetano Mangiapia; Mauro Vaccaro; Eliana Gianolio; Richard K Heenan; Luigi Paduano; Giancarlo Morelli
Journal:  J Biol Inorg Chem       Date:  2009-02-03       Impact factor: 3.358

5.  Comparison of side effects of pentagastrin test and calcium stimulation test in patients with increased basal calcitonin concentration: the gender-specific differences.

Authors:  Philipp Ubl; Tatiana Gincu; Mohammad Keilani; Lothar Ponhold; Richard Crevenna; Bruno Niederle; Marcus Hacker; Shuren Li
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

6.  DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.

Authors:  Maximilian Klingler; Dominik Summer; Christine Rangger; Roland Haubner; Julie Foster; Jane Sosabowski; Clemens Decristoforo; Irene Virgolini; Elisabeth von Guggenberg
Journal:  J Nucl Med       Date:  2018-12-07       Impact factor: 10.057

Review 7.  Nuclear imaging of molecular processes in cancer.

Authors:  Rafael Torres Martin de Rosales; Erik Arstad; Philip J Blower
Journal:  Target Oncol       Date:  2009-09-25       Impact factor: 4.493

Review 8.  Peptides and peptide hormones for molecular imaging and disease diagnosis.

Authors:  Seulki Lee; Jin Xie; Xiaoyuan Chen
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

9.  CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Paola Moreno; Robert T Jensen
Journal:  J Mol Neurosci       Date:  2015-03-12       Impact factor: 3.444

10.  Progastrin Peptides Increase the Risk of Developing Colonic Tumors: Impact on Colonic Stem Cells.

Authors:  Pomila Singh; Shubhashish Sarkar; Carla Kantara; Carrie Maxwell
Journal:  Curr Colorectal Cancer Rep       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.